RxDoctor Payments DataLook up a doctor →

Michael Rosenberg, MD

Interventional Cardiology · Manitowoc, WINPI 1356385330

Payments from drug & device makers

$203,343in general payments, 2019–2025

Across 473 payments — averaging $429.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$88K
  • Sanofi US Services Inc.$30K
  • Regeneron$27K
  • Bayer$15K
  • Novartis$14K
  • CSL Behring$13K
  • plus $17K from 35 others

What the payments were for

  • Consulting fees$9,0918%
  • Speaking & faculty fees$80,30072%
  • Travel & lodging$10,89410%
  • Food & beverage$11,04310%
  • Education$320%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$203,343 in reported general payments places this provider in the 90th percentile of 118 interventional cardiology providers in Wisconsin.

See all interventional cardiology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$172,163
Medicare patients
1,338
Services billed
5,350

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban195$194,106
EntrestoSacubitril/Valsartan123$191,405
EliquisApixaban136$138,908
BrilintaTicagrelor141$127,812
JardianceEmpagliflozin84$100,602
FarxigaDapagliflozin Propanediol73$70,602
Repatha SureclickEvolocumab24$26,199
DapagliflozinDapagliflozin Propanediol11$8,854
Metoprolol Succinate394$5,126
ClopidogrelClopidogrel Bisulfate427$4,853
Rosuvastatin Calcium308$4,399
Atorvastatin Calcium289$3,136
Losartan Potassium243$2,229
Ranolazine ErRanolazine19$1,811
Digoxin49$1,770

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta, Farxiga$3,947$198,414214 claims
Johnson & JohnsonXarelto$87,563$194,106195 claims
NovartisEntresto$13,782$191,405123 claims
PfizerEliquis$2,151$138,908136 claims
Boehringer IngelheimJardiance$20$100,60284 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 118 interventional cardiology providers in Wisconsin.

Other interventional cardiology in Manitowoc

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →